Moderna Inc
Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
Artur Widak | Nurphoto | Getty Images Shares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock has […]
Read More
Stocks earning the greatest moves midday: Moderna, Apple, GoodRx, Coinbase and additional
Look at out the corporations generating headlines in midday trading. Moderna — The drugmaker jumped 16% pursuing an up grade to outperform by Oppenheimer. The company said Moderna’s several products launches in the upcoming 12 to 18 months should support top rated-line product sales start out to improve in 2025. Moderna fell additional than 40% […]
Read More
Here are the big health sector themes to watch next year
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and […]
Read More
Treasury yields fall as traders continue on to evaluate potential clients of futures Fed level cuts
The 10-12 months U.S. Treasury produce retreated on Tuesday, reversing training course from the former day’s trade and continuing a basic downward craze about the past 7 days. The produce on the benchmark 10-12 months take note was down 5 basis factors at 3.907%, having fallen below 4% on Thursday to strike its least expensive […]
Read More
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
An exterior view of Moderna’s clinical manufacturing facility. David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage […]
Read More
Pfizer shares fall as 2024 revenue and profit forecast disappoints
Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion. The company expects 2024 revenue of $58.5 billion […]
Read More
Treasury yields inch increased in advance of Fed meeting
U.S. Treasury yields have been fractionally better on Monday, as investors appear ahead to this week’s Federal Reserve policy meeting. The yield on the benchmark 10-calendar year Treasury observe was just in excess of a solitary foundation stage higher at 4.2563%, although the produce on the 30-yr Treasury bond was just underneath a level greater […]
Read More
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
A sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | Reuters Three years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine. Only 15.7% of U.S. adults had received the newest Covid shots from Pfizer, Moderna and Novavax […]
Read More
Stocks building the biggest moves midday: Starbucks, Roku, Eli Lilly, Affirm and more
Check out out the firms creating headlines in midday buying and selling. Starbucks — Shares jumped much more than 10% immediately after the business posted an earnings and income conquer in the fiscal fourth quarter. Administration also described far better-than-anticipated general performance in China, its second-biggest sector. Roku — The streaming online video platform rallied […]
Read More
Moderna stock falls 10% as hefty Covid vaccine write-downs drive big loss
Moderna on Thursday posted a steep loss for the third quarter as the drugmaker recorded a large write-down due to unused doses of its Covid vaccine, its only marketable product. Moderna’s total revenue for the period topped Wall Street’s expectations, even amid plummeting demand for its shot. Its outlook for next year, however, came in […]
Read More